↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Lisata Therapeutics$LSTA · filed: saw revenue fall 83.0% in FY2025 to $0MRotting at the dockNext year $0.0M–$0.1M sealedCheck ▾Close ▴
What Lisata Therapeutics filed
Saw revenue fall 83.0% in FY2025 to $0 million, operating margin -10711% against a -3.8% median for pharmaceutical preparations, equity 83.7% of assets. Every figure links to the filing it came from on Lisata Therapeutics’s card. Rotting at the dock: four or more warning signs.
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $0.0M and $0.1M, an 80% range sealed on 20 Sept 2026 · receipt #28cfba · graded in public by the revenue in Lisata Therapeutics’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Kuva's tender bifurcates Lisata's valuation into immediate **$4.00** cash and deferred regulatory upside, forcing holders to price their own clinical confidence.
$4.00
per share in cash
$140 million
on a fully diluted basis before CVR consideration
$5.20
over the trailing twelve months
43%
above yesterday's close of
Kuva Labs commenced a tender offer for Lisata Therapeutics at $4.00 per share in cash, plus one non-tradeable contingent value right tied to future clinical and regulatory milestones. The offer opened this week without prior leak, pricing Lisata's equity at roughly $140 million on a fully diluted basis before CVR consideration.
Lisata, a clinical-stage oncology developer focused on its lead asset certepetide, has traded between $2.80 and $5.20 over the trailing twelve months. The $4.00 cash component sits 43% above yesterday's close of $2.80 and represents a modest premium to the six-month volume-weighted average of $3.65. The CVR attaches value to three distinct events: FDA approval of certepetide in metastatic pancreatic cancer, European regulatory clearance, and subsequent commercial milestones tied to net sales thresholds. The rights are non-tradeable, cannot be separated from the cash consideration, and expire worthless if the regulatory triggers fail to materialize within specified timeframes.
The structure is precise arbitrage against clinical risk. Kuva, a private acquisition vehicle backed by a family office network, pays a control premium for the equity today while deferring the bulk of valuation risk to contingent payments. If certepetide clears pivotal trial readouts and regulatory hurdles, shareholders participate in milestone value without holding illiquid equity through development risk. If the asset fails, Kuva limits loss to the upfront cash plus deal costs. For Lisata shareholders, the choice is immediate liquidity at a known price or continued exposure to a single-asset binary with dilution risk if the company needs additional capital before data.
The CVR design matters for how family offices and crossover funds will model this. Non-tradeability means no secondary market will emerge to price the contingent rights, so shareholders must hold through payouts or abandon the CVR upon tendering. The milestones themselves are binary: either the FDA grants approval or the right expires. This eliminates the gradual mark-to-market that comes with publicly traded equity but introduces valuation ambiguity for funds required to fair-value holdings quarterly. Allocators who tendered into similar structures—Celldex's $0.75 CVR in 2020, Ignyta's $3.00 milestone rights in 2018—saw those instruments either pay out in full or expire worthless with no intermediate recovery.
Watch for Lisata's top-20 shareholders to file Schedule 14D-9 amendments within ten days, signaling tender intent or opposition. Kuva will need acceptance from holders of a majority of outstanding shares to close. If opposition materializes, the offer price could rise or the CVR terms could broaden to include earlier-stage milestones. The certepetide Phase 3 trial in metastatic pancreatic cancer is expected to read out in Q4 2025, creating a 20-month runway between now and the primary value inflection.
The offer expires 30 days from commencement unless extended. By then, the market will know whether Kuva controls Lisata or whether the company remains independent and returns to capital-raising mode.
Branded by POPS4 · proof in 60 seconds
For the principal
If you hold Lisata, model the CVR at zero and decide if $4.00 cash exceeds your internal certepetide probability-weighted NAV.
For the operator
Track 13D filings from Lisata's top-20 within ten days; significant opposition could force Kuva to sweeten the upfront or milestone schedule.
For the house
We closed our Lisata position at $3.85 in January; no reentry here—CVR illiquidity doesn't compensate for single-asset clinical risk at this price.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
